Cedar Mountain Advisors
PTGX icon

Cedar Mountain Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Cedar Mountain Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.9K Hold
113
– – ﹤0.01% 353
2026
Q2 		$13.9K Hold
113
– – ﹤0.01% 426
2026
Q1 		$11.9K Buy
+113
New +$10K ﹤0.01% 418

Other funds holding PTGX

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Exchange Traded Concepts
Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Cedar Mountain Advisors's PTGX Position: Q3 2026 in Review

Cedar Mountain Advisors held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 113 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Cedar Mountain Advisors first reported a position in PTGX in Q1 2026 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Cedar Mountain Advisors held 113 shares of Protagonist Therapeutics worth $15.9K as of Q3 2026.
  • Cedar Mountain Advisors left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #353 holding.
  • Cedar Mountain Advisors first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 89 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.